Marco Investment Management Increased Its Aflac (AFL) Stake; Acceleron Pharma (XLRN) Shorts Increased By 0.03%

Aflac Incorporated (NYSE:AFL) Logo

Acceleron Pharma Inc (NASDAQ:XLRN) had an increase of 0.03% in short interest. XLRN’s SI was 2.77M shares in June as released by FINRA. Its up 0.03% from 2.77 million shares previously. With 268,400 avg volume, 10 days are for Acceleron Pharma Inc (NASDAQ:XLRN)’s short sellers to cover XLRN’s short positions. The SI to Acceleron Pharma Inc’s float is 7.19%. The stock increased 28.90% or $9.82 during the last trading session, reaching $43.8. About 971,335 shares traded or 197.03% up from the average. Acceleron Pharma Inc. (NASDAQ:XLRN) has risen 37.77% since June 29, 2017 and is uptrending. It has outperformed by 25.20% the S&P500. Some Historical XLRN News: 22/03/2018 – CAFC: DELL INC. v. ACCELERON, LLC [ERRATA] – Appeal #17-1101 – 2018-03-22; 07/05/2018 – Acceleron at Deutsche Bank Health Care Conference Tomorrow; 08/05/2018 – ACCELERON 1Q LOSS/SHR 58C, EST. LOSS/SHR 65C; 26/04/2018 – Acceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual Meeting; 21/05/2018 – Acceleron Presenting at UBS Conference Tomorrow; 22/05/2018 – Acceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension; 01/05/2018 – Acceleron Pharma: ACE-083 Is Currently Being Evaluated in Two Phase 2 Trials: One in FSHD and One in Charcot-Marie-Tooth Disease; 01/05/2018 – Acceleron Receives FDA Fast Track Designation For ACE-083 In Facioscapulohumeral Muscular Dystrophy (FSHD); 26/04/2018 – Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology Annual Meeting; 01/05/2018 – ACCELERON GETS FDA FAST TRACK FOR ACE-083 IN FSHD

Marco Investment Management Llc increased Aflac Inc (AFL) stake by 102.09% reported in 2018Q1 SEC filing. Marco Investment Management Llc acquired 68,424 shares as Aflac Inc (AFL)’s stock declined 0.09%. The Marco Investment Management Llc holds 135,448 shares with $5.93 million value, up from 67,024 last quarter. Aflac Inc now has $33.59 billion valuation. The stock increased 0.42% or $0.18 during the last trading session, reaching $43.39. About 63,004 shares traded. Aflac Incorporated (NYSE:AFL) has risen 21.38% since June 29, 2017 and is uptrending. It has outperformed by 8.81% the S&P500. Some Historical AFL News: 02/04/2018 – Moody’s Assigns First-time Aa3 Ifsr To Aflac Japan; Outlook Stable; 09/05/2018 – Aflac Brings Home SABRE Awards for Corporate Responsibility, Including Top Award for Best in Show; 02/04/2018 – A.M. Best Assigns Credit Ratings to Aflac’s New Japan Subsidiary; Affirms Credit Ratings of U.S. Insurance Subsidiaries; 25/04/2018 – AFLAC INC AFL.N SEES FY 2018 SALES UP 3 TO 5 PCT; 26/04/2018 – Plexus Partner Mitchell Andrews Featured in Aflac’s Annual Report; 17/05/2018 – Aflac, Commonwealth Bank of Australia, Google, and Liberty Global Join PegaWorld 2018 Keynote Lineup; 02/04/2018 – AFLAC AFFIRMED BY FITCH, OUTLOOK STABLE; 04/04/2018 – Aflac Recognized for Social Responsibility; 03/04/2018 – Aflac Names J. Todd Daniels as EVP; Principal Fincl Officer, Aflac Japan and Albert a. Riggieri as SVP, Global Chief Risk Officer and Chief Actuary, Aflac Inc; 25/04/2018 – Aflac 1Q Adj EPS $1.05

Investors sentiment increased to 1.27 in Q1 2018. Its up 0.18, from 1.09 in 2017Q4. It improved, as 13 investors sold Acceleron Pharma Inc. shares while 39 reduced holdings. 24 funds opened positions while 42 raised stakes. 38.30 million shares or 0.44% more from 38.14 million shares in 2017Q4 were reported. State Board Of Administration Of Florida Retirement Systems invested 0% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN). Eventide Asset Mngmt reported 529,900 shares or 0.97% of all its holdings. Bluemountain Capital Mngmt Ltd Company owns 2,419 shares for 0% of their portfolio. 28,588 were accumulated by Putnam Invs Lc. Granahan Inv Management Incorporated Ma has 232,746 shares. Royal Bank Of Canada owns 32 shares. First Trust Advisors L P holds 32,354 shares or 0% of its portfolio. Citigroup has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). The Illinois-based Envestnet Asset Management has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Barclays Public Ltd Co has invested 0% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN). Fmr Llc reported 5.17 million shares. Artal Group Sa accumulated 850,000 shares. 163,900 were reported by Baker Bros Advsrs Lp. Bankshares Of America Corp De invested in 0% or 57,195 shares. Hillhouse Mgmt Ltd stated it has 700,000 shares.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company has market cap of $2.01 billion. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. It currently has negative earnings. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

Since January 2, 2018, it had 0 insider purchases, and 12 insider sales for $4.08 million activity. Another trade for 4,600 shares valued at $176,772 was sold by Sherman Matthew L. $1.55 million worth of stock was sold by POPS RICHARD F on Tuesday, March 6. The insider Rovaldi Christopher sold $134,395. The insider Kumar Ravindra sold $46,205. Quisel John D sold $183,806 worth of stock. MCLAUGHLIN KEVIN F also sold $153,792 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) on Tuesday, April 3.

More notable recent Acceleron Pharma Inc. (NASDAQ:XLRN) news were published by: Streetinsider.com which released: “Form 8-K ACCELERON PHARMA INC For: Jun 15” on June 20, 2018, also Seekingalpha.com with their article: “Acceleron: Luspatercept New Data Is A Buy Signal” published on June 07, 2018, Benzinga.com published: “Benzinga’s Top Upgrades, Downgrades For June 29, 2018” on June 29, 2018. More interesting news about Acceleron Pharma Inc. (NASDAQ:XLRN) were released by: Streetinsider.com and their article: “Pre-Open Movers 06/29: (GEMP) (DERM) (NKE) Higher; (PFIE) (STZ) (SNX) Lower (more…)” published on June 29, 2018 as well as 247Wallst.com‘s news article titled: “Top Analyst Upgrades and Downgrades: Accenture, Ally, Diageo, Harley-Davidson, KB Home, NetApp, Nike, Sirius XM …” with publication date: June 29, 2018.

Among 5 analysts covering Acceleron Pharma (NASDAQ:XLRN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Acceleron Pharma had 7 analyst reports since January 8, 2018 according to SRatingsIntel. As per Thursday, March 1, the company rating was maintained by Citigroup. The rating was initiated by H.C. Wainwright with “Buy” on Wednesday, March 28. As per Monday, January 8, the company rating was initiated by H.C. Wainwright. The stock has “Buy” rating by H.C. Wainwright on Wednesday, February 28. Oppenheimer initiated Acceleron Pharma Inc. (NASDAQ:XLRN) on Tuesday, May 22 with “Hold” rating. JP Morgan upgraded Acceleron Pharma Inc. (NASDAQ:XLRN) on Monday, February 26 to “Overweight” rating. The company was maintained on Wednesday, February 28 by Barclays Capital.

Among 13 analysts covering AFLAC Inc (NYSE:AFL), 4 have Buy rating, 1 Sell and 8 Hold. Therefore 31% are positive. AFLAC Inc had 15 analyst reports since January 9, 2018 according to SRatingsIntel. Raymond James upgraded it to “Buy” rating and $100.0 target in Monday, January 22 report. Wells Fargo maintained Aflac Incorporated (NYSE:AFL) on Tuesday, January 9 with “Hold” rating. The firm earned “Hold” rating on Thursday, February 1 by Sandler O’Neill. Sandler O’Neill maintained Aflac Incorporated (NYSE:AFL) rating on Thursday, April 5. Sandler O’Neill has “Hold” rating and $4700 target. The stock of Aflac Incorporated (NYSE:AFL) earned “Hold” rating by Barclays Capital on Wednesday, March 21. As per Tuesday, March 27, the company rating was maintained by JP Morgan. SunTrust maintained it with “Hold” rating and $92.0 target in Thursday, February 1 report. The firm has “Sell” rating by RBC Capital Markets given on Thursday, February 1. The rating was maintained by Keefe Bruyette & Woods on Tuesday, March 20 with “Hold”. Bank of America maintained Aflac Incorporated (NYSE:AFL) rating on Monday, March 26. Bank of America has “Neutral” rating and $49 target.

Since February 16, 2018, it had 2 insider buys, and 4 insider sales for $2.81 million activity. On Tuesday, February 20 the insider MOSKOWITZ JOSEPH L bought $49,022. 10,000 shares valued at $437,155 were sold by KNAPP CHARLES B on Monday, March 26. $239,194 worth of stock was sold by HOWARD JUNE P on Wednesday, February 28. Lloyd Karole bought $178,090 worth of stock. Shares for $117,123 were sold by TILLMAN AUDREY B on Wednesday, February 28. $2.24M worth of Aflac Incorporated (NYSE:AFL) shares were sold by AMOS DANIEL P.

Marco Investment Management Llc decreased Nxp Semiconductors N V (NASDAQ:NXPI) stake by 6,200 shares to 51,450 valued at $6.02 million in 2018Q1. It also reduced General Electric Co (NYSE:GE) stake by 32,087 shares and now owns 232,527 shares. Unitedhealth Group Inc (NYSE:UNH) was reduced too.

Aflac Incorporated (NYSE:AFL) Institutional Positions Chart